Oncology drug development with three drug candidates in renal cell carcinoma, CD30-positive lymphomas, and breast cancer; early clinical development with Phase 1/1b programs.
AI-supported drug discovery
AI-supported drug discovery to identify optimal therapeutic areas for molecules, analyse publicly available life-science data, and accelerate clinical decisions.
Asset licensing and development partnerships
Asset licensing and development partnerships for flexible collaboration with biopharma companies, including financing and de-risked clinical development.
Comparisons
Oncoteq AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Oncoteq AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Oncoteq AG has claimed this profile, we'll publish editorial articles and case studies here together.